Journals / Türk Nöroşirürji Dergsi / 2021 / Cilt: 31 - Sayı: 1

Craniopharyngioma in the Pediatric Population

Pediatrik Popülasyonda Kraniyofarengiom

Pages
125–134
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recent developments show promise for target-based molecular therapies for inhibition of specific pathways, but further studies are needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Craniopharyngiomas are rare sellar / suprasellar tumors.
📊
Key Findings & Data:Although these tumors, which can be seen in both pediatric and adult age groups, are considered benign, high morbidity rates in the long term have increased the medicopsychosocial burden of the disease.
💡
Conclusion & Impact:Recent developments show promise for target-based molecular therapies for inhibition of specific pathways, but further studies are needed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Craniopharyngiomas are rare sellar / suprasellar tumors. Although these tumors, which can be seen in both pediatric and adult age groups, are considered benign, high morbidity rates in the long term have increased the medicopsychosocial burden of the disease. Almost all of the pediatric craniopharyngioma cases are of the adamantinomatous type. These tumors are closely adjacent to structures such as the optic apparatus, pituitary, hypothalamus, Willis polygon, and brain stem. Hypothalamic involvement significantly increases mortality and morbidity rates in such cases. Although the treatment of craniopharyngioma seems to be determined basically, it can become quite controversial in complicated cases. The need to maintain the balance between tumor control and quality of life has formed the basic rule in the treatment of this patient population. The management of craniopharyngioma patients is a challenging process and should be followed by multidisciplinary teams consisting of neurosurgeons, neurologists, oncologists, endocrinologists, and ophthalmologists. Recent developments show promise for target-based molecular therapies for inhibition of specific pathways, but further studies are needed.

Özet

Kraniyofarengiomlar nadir görülen sellar/suprasellar bölge tümörleridir. Pediatrik ve erişkin her iki yaş grubunda görülebilen butümörler iyi huylu olarak kabul edilmelerine rağmen uzun vadede yüksek morbidite oranları hastalığın medikopsikososyal yükünüartırmıştır. Pediatrik kraniyofarengiom olgularının neredeyse tamamı adamantinomatöz tiptedir. Bu tümörler optik aparat, hipofiz,hipotalamus, Willis poligonu ve beyin sapı gibi yapılara yakın komşuluk gösterirler. Hipotalamik tutulum veya etkilenme olgularınmortalite ve morbidite oranlarını önemli ölçüde artırır. Kraniyofarengiom tedavisi temelde belirlenmiş görünmekle beraber komplikeolgularda oldukça tartışmalı hâle gelebilmektedir. Tümör kontrolü ile yaşam kalitesi arasındaki dengenin korunması gerektiği, buhasta popülasyonunun tedavisinde temel kuralı oluşturmuştur. Kraniyofarengiom hastalarının yönetilmesi zorlu bir süreç olupnöroşirürjiyen, nörolog, onkolog, endokrinolog ve oftalmologların bulunduğu multidisipliner ekipler tarafından izlenmesi gereklidir.Son gelişmeler belirli yolakların inhibisyonuna yönelik hedef-bazlı kişiye özel moleküler tedavilere yönelik umut vadetmektedir ancakileri çalışmaların yapılmasına gerek duyulmaktadır.

🔖

Cite This Article

BAYATLI, E., KAHILOĞULLARI, G. (2022). Craniopharyngioma in the Pediatric Population. Türk Nöroşirürji Dergsi, Cilt: 31 - Sayı: 1, 125–134. https://ajindex.com/articles/637188

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Akinduro OO, Izzo A, Lu VM, Ricciardi L, Trifiletti D, Peterson JL, Bernet V, Donaldson A, Eggenberger E, Olomu O, Reimer R, Wharen R, Quinones-Hinojosa A, Chaichana KL: Endocrine and visual outcomes following gross total resection and subtotal resection of adult craniopharyngioma: Systematic review and meta-analysis. World Neurosurg 127:e656-e668, 2019 2. Ali ZS, Bailey RL, Daniels LB, Vakhshori V, Lewis DJ, Hossain AT, Sitterley KY, Lee JYK, Storm PB, Heuer GG, Stein SC: Comparative effectiveness of treatment options for pediatric craniopharyngiomas. J Neurosurg Pediatr 13(2):178-188, 2014 3. Apps JR, Martinez-Barbera JP: Molecular pathology of adamantinomatous craniopharyngioma: Review and opportunities for practice. Neurosurg Focus 41(6):E4, 2016 4. Caldarelli M, Massimi L, Tamburrini G, Cappa M, Di Rocco C: Long-term results of the surgical treatment of craniopharyngioma: The experience at the Policlinico Gemelli, Catholic University, Rome. Child’s Nerv Syst 21:747-757, 2005 5. Cavallo LM, Prevedello DM, Solari D, Gardner PA, Esposito F, Snyderman CH, Carrau RL, Kassam AB, Cappabianca P: Extended endoscopic endonasal transsphenoidal approach for residual or recurrent craniopharyngiomas. J Neurosurg 111(3):578-589, 2009 6. Chivukula S, Koutourousiou M, Snyderman CH, FernandezMiranda JC, Gardner PA, Tyler-Kabara EC: Endoscopic endonasal skull base surgery in the pediatric population. J Neurosurg Pediatr 11(3):227-241, 2013 7. Clark AJ, Cage TA, Aranda D, Parsa AT, Sun PP, Auguste KI, Gupta N: A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma. Childs Nerv Syst 29(2):231-238, 2013 8. Cohen M, Guger S, Hamilton J: Long term sequelae of pediatric craniopharyngioma - literature review and 20 years of experience. Front Endocrinol 2:81, 2011 9. Conger AR, Lucas J, Zada G, Schwartz TH, Cohen-Gadol AA: Endoscopic extended transsphenoidal resection of craniopharyngiomas: Nuances of neurosurgical technique. Neurosurg Focus 37(4):E10, 2014 10. Deopujari CE, Karmarkar VS, Shah N, Vashu R, Patil R, Mohanty C, Shaikh S: Combined endoscopic approach in the management of suprasellar craniopharyngioma. Childs Nerv Syst 34(5):871-876, 2018 11. Desiderio C, Rossetti DV, Castagnola M, Massimi L, Tamburrini G: Adamantinomatous craniopharyngioma: Advances in proteomic research. Childs Nerv Syst 36:1635-1642, 2020 12. Elliott RE, Hsieh K, Hochm T, Belitskaya-Levy I, Wisoff J, Wisoff JH: Efficacy and safety of rad